⌕
Xeris Biopharma Holdings · XERS · Nasdaq
Tenet 48 · Mixed
Compare
$16.70+0.24%At closeTenet 48 · Mixed
$16.70+0.04 (+0.24%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Xeris Biopharma Holdings (XERS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

Business engineGrowing fast: revenue compounds ~55.8%/yr (FY21→FY25), net margin 0.2%, and free cash flow (~$27.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+118.6%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($K)▲43.7%
291,845.0
FY21→FY25CAGR +55.8%/yr
Net income ($K)—
554.0
FY21→FY25CAGR —
Free cash flow ($K)—
27,930.0
FY21→FY25CAGR —
Diluted EPS—
0.00
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+118.6%

79.0mn → 172.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$696.0K

−19.8% YoY in FY25 · 0.2% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)291845.0Revenue−42569.0COGS249276.0Gross profit−31165.0R&D−182372.0SG&A24896.0Op income−24342.0Tax & other554.0Net income

0¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
906845230%sector median net margin ~4%FY21FY25

Over this window: gross 73.1% → 85.4%. Net margin 0.2% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
368,259.0291,845.0203,070.0163,914.0110,248.049,590.0▲43.7%+55.8%
Cost of revenue
46,462.042,569.036,832.028,645.022,634.013,318.0▲15.6%+33.7%
Gross profit
321,797.0249,276.0166,238.0135,269.087,614.036,272.0▲50.0%+61.9%
Research & development
38,384.031,165.025,560.022,341.020,966.025,160.0▲21.9%+5.5%
Selling, general & admin
225,789.0182,372.0163,481.0146,095.0137,745.0125,718.0▲11.6%+9.7%
Total operating expenses
275,016.0224,380.0199,884.0179,279.0169,554.0151,428.0▲12.3%+10.3%
Operating incomefeeds ROC rank
46,781.024,896.0−33,646.0−44,010.0−81,940.0−115,156.0——
Other income, net
−53,277.0−24,342.0−23,458.0−19,494.0−14,144.0−7,569.0——
Pretax income
−6,496.0554.0−57,104.0−63,504.0−96,084.0−122,725.0——
Income tax
—0.0−2,268.0−1,249.0−1,424.00.0——
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
−6,496.0554.0−54,836.0−62,255.0−94,660.0−122,725.0——
Per share
Diluted EPSbuyback-sensitive
−0.040.00−0.37−0.45−0.70−1.55——
Diluted shares (mn)
189.92172.74146.77137.67135.6379.03▲17.7%+21.6%
Margins
Gross margin82nd pct in Healthcare
87.4%85.4%81.9%82.5%79.5%73.1%▲3.6pp+12.3pp
Operating margin
12.7%8.5%−16.6%−26.8%−74.3%−232.2%▲25.1pp+240.7pp
Net margin36th pct in Healthcare
−1.8%0.2%−27.0%−38.0%−85.9%−247.5%▲27.2pp+247.7pp
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Xeris Biopharma Holdings' revenue last fiscal year?

Xeris Biopharma Holdings reported revenue of $291,845.0K in fiscal 2025, up 43.7% from fiscal 2024.

What was Xeris Biopharma Holdings' net income?

Xeris Biopharma Holdings reported net income of $554.0K in fiscal 2025, a net margin of 0.2%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.